197 related articles for article (PubMed ID: 22451700)
1. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V; Solà J; Peraire C; Brée F; Obach R
Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification.
Ventura V; Solà J; Celma C; Peraire C; Obach R
Drug Metab Dispos; 2011 Jul; 39(7):1235-46. PubMed ID: 21464173
[TBL] [Abstract][Full Text] [Related]
3. Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes.
Jeong HU; Lee JY; Kwon SS; Kim JH; Kim YM; Hong SW; Yeon SH; Lee SM; Cho YY; Lee HS
Arch Pharm Res; 2015 Feb; 38(2):171-7. PubMed ID: 25052959
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
5. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
[TBL] [Abstract][Full Text] [Related]
7. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Kim J; Peraire C; Solà J; Johanning KM; Dalton JT; Veverka KA
Xenobiotica; 2011 Oct; 41(10):851-62. PubMed ID: 21726172
[TBL] [Abstract][Full Text] [Related]
8. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo Z; Raeissi S; White RB; Stevens JC
Drug Metab Dispos; 1997 Mar; 25(3):390-3. PubMed ID: 9172960
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Sonesson A; Rasmussen BB
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
Zhou D; Andersson TB; Grimm SW
Drug Metab Dispos; 2011 Apr; 39(4):703-10. PubMed ID: 21177984
[TBL] [Abstract][Full Text] [Related]
12. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
[TBL] [Abstract][Full Text] [Related]
17. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
18. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
[TBL] [Abstract][Full Text] [Related]
19. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
Gan J; Liu-Kreyche P; Humphreys WG
Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
